Biodegradation of Uric Acid by Bacillus paramycoides-YC02

Xiaoyu Cao,Jingyuan Cai,Yu Zhang,Chao Liu,Meijie Song,Qianqian Xu,Yang Liu,Hai Yan

DOI: https://doi.org/10.3390/microorganisms11081989

IF: 4.5

2023-08-02

Microorganisms

Abstract:High serum uric acid levels, known as hyperuricemia (HUA), are associated with an increased risk of developing gout, chronic kidney disease, cardiovascular disease, diabetes, and other metabolic syndromes. In this study, a promising bacterial strain capable of biodegrading uric acid (UA) was successfully isolated from Baijiu cellar mud using UA as the sole carbon and energy source. The bacterial strain was identified as Bacillus paramycoides-YC02 through 16S rDNA sequence analysis. Under optimal culture conditions at an initial pH of 7.0 and 38 °C, YC02 completely biodegraded an initial UA concentration of 500 mg/L within 48 h. Furthermore, cell-free extracts of YC02 were found to catalyze and remove UA. These results demonstrate the strong biodegradation ability of YC02 toward UA. To gain further insight into the mechanisms underlying UA biodegradation by YC02, the draft genome of YC02 was sequenced using Illumina HiSeq. Subsequent analysis revealed the presence of gene1779 and gene2008, which encode for riboflavin kinase, flavin mononucleotide adenylyl transferase, and flavin adenine dinucleotide (FAD)-dependent urate hydroxylase. This annotation was based on GO or the KEEG database. These enzymes play a crucial role in the metabolism pathway, converting vitamin B2 to FAD and subsequently converting UA to 5-hydroxyisourate (HIU) with the assistance of FAD. Notably, HIU undergoes a slow non-enzymatic breakdown into 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) and (S)-allantoin. The findings of this study provide valuable insights into the metabolism pathway of UA biodegradation by B. paramycoides-YC02 and offer a potential avenue for the development of bacterioactive drugs against HUA and gout.

microbiology

What problem does this paper attempt to address?

The problem this paper attempts to address is the health risks associated with high levels of uric acid (hyperuricemia, HUA). Hyperuricemia is related to various metabolic syndromes such as gout, chronic kidney disease, cardiovascular diseases, and diabetes. Currently, the management of HUA mainly relies on medication and dietary interventions, but these methods have issues such as potential side effects and reduced efficacy with long-term use. Therefore, researchers are looking for new methods to effectively manage and treat HUA.

In this study, researchers isolated a bacterium capable of efficiently degrading uric acid from baijiu cellar mud—**Bacillus paramycoides -YC02**. By optimizing the culture conditions, researchers found that this bacterium could completely degrade 500 mg/L of uric acid within 48 hours under conditions of an initial pH of 7.0 and a temperature of 38°C. Additionally, through genome sequencing and functional annotation, researchers revealed the mechanism by which this bacterium degrades uric acid, discovering genes encoding riboflavin kinase, flavin mononucleotide adenylyltransferase, and FAD-dependent urate hydroxylase. These enzymes play a key role in the uric acid metabolism pathway, converting uric acid to 5-hydroxyisourate (HIU), which then non-enzymatically decomposes into 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) and (S)-allantoin.

In summary, this study provides an important theoretical foundation and experimental basis for developing bacterial active drugs targeting HUA and gout.